Latest Breaking News On - Exavir therapeutics inc - Page 1 : comparemela.com

Exavir Therapeutics Receives $3M Award from NIH / NIAID to Advance Ultra-Long-Acting Integrase Inhib

SAN FRANCISCO (BUSINESS WIRE) Exavir Therapeutics, a company dedicated to transforming the lives of patients with chronic viral infections and CNS disorders with ultra-long-acting therapeutics, today announced that the company has received a $3M award from the National Institute of Allergy and Infectious Diseases.

San franciscoUnited statesMark cockettAlborz yazdiBrian kearneyNational institute of allergyExavir therapeutics incNational institute of healthExavir therapeuticsNational instituteInfectious diseasesChief scientific advisorChief scientific officer

Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV

Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Benson edagwaHoward gendelmanNature communicationsExavir therapeutics incUniversity of nebraska medical centerDepartment of pharmacologyExavir therapeuticsAssociate professorNebraska medicalஇயற்கை தகவல்தொடர்புகள்பல்கலைக்கழகம் ஆஃப் நெப்ராஸ்கா மருத்துவ மையம்துறை ஆஃப் மருந்தியல்இணை ப்ரொஃபெஸர்நெப்ராஸ்கா மருத்துவ